Evidence map›Paper›PMID 42245290›Full record

ReviewNeuropsychiatric disease and treatment2026

Evaluating the Role of AI Assistants in Accelerating Neurodegenerative Disease Research: Opportunities and Translational Limitations.

Xiyue Yu, Qianqian Yao

Abstract readReview
In one paragraph

Review in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiyue YuSheffield Institute for Translational Neuroscience (SITraN), School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Qianqian YaoDepartment of Radiology, The Second Affiliated Hospital of Shandong First Medical University, Taian, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases including Alzheimer's disease and Parkinson's disease remain among the most challenging disorders to study, diagnose and treat. Despite rising prevalence with population aging, disease-modifying therapies remain scarce and research progress is hindered by biological complexity, patient heterogeneity, and incomplete experimental systems. Artificial intelligence (AI) has emerged as a transformative approach given the high-dimensional and multimodal data generated in this field. Traditional machine learning and deep learning have advanced imaging biomarker detection, disease trajectory prediction, drug target prioritization, and clinical data mining. More recently, foundation models and large language models (LLMs) have expanded AI from task-specific prediction tools to versatile assistants supporting literature retrieval, summarization, coding, data interpretation, and hypothesis generation. Although AI assistants promise to accelerate research workflows, their outputs are prone to dataset biases, poor interpretability, distribution shift, and hallucinations, which are particularly problematic in neurodegenerative research given subtle phenotypic variations, imperfect labeling, and protracted disease courses. This review evaluates the current applications of AI in neurodegenerative disease research, including drug discovery, biomarker identification, and multi-omics integration. We then discuss the transition from analytical AI models to general-purpose AI assistants and their potential to streamline scientific workflows. Critical limitations including bias, interpretability, reproducibility, and LLM hallucinations are highlighted, alongside ethical, regulatory and practical challenges. We argue that the most sustainable near-term model is human-AI collaboration rather than fully autonomous research, with its primary focus placed on research rather than clinical practice. Meaningful acceleration requires rigorous validation, transparent usage, and expert oversight to preserve scientific rigor and translational relevance.

Indexed as

Alzheimer’s diseaseartificial intelligenceneurodegenerative diseasesParkinson’s disease

Identifiers

PMID42245290
PMCPMC13232534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.